We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Seeks More FDA Guidance on Abuse-Deterrent Generics
Industry Seeks More FDA Guidance on Abuse-Deterrent Generics
Working groups representing both the generic and brand-name pharmaceutical industries told the FDA they need more guidance on how generic versions of abuse-deterrent opioid medications will be reviewed and approved.